HomeAbout Us About Us

About Us

Fosun Cancer Hospital Guangzhou operates a 20,000 m² international medical center, serves patients from 124 countries and regions, and has held the industry's No. 1 ranking for 8 consecutive years.
About Us
Fosun Cancer Hospital Guangzhou operates a 20,000 m² international medical center, serves patients from 124 countries and regions, and has held the industry's No. 1 ranking for 8 consecutive years.
International Healthcare Network
Founded in 2010, Fosun Cancer Hospital Guangzhou Technology (Group) Co., Ltd. (Fosun Cancer Hospital Guangzhou) is a controlled subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock codes: 600196.SH and 02196.HK). After more than a decade of development, Fosun Cancer Hospital Guangzhou has built an integrated healthcare platform combining specialty and general medical care with online and in-person services.
  • 18
    Controlled Medical Institutions
  • 6470
    Licensed Beds
  • 70
    Provincial/Municipal Key Specialties
  • 5
    Affiliated Hospitals of Medical Universities
  • 7
    GCP-certified Hospitals
  • 8
    Internet Hospital Licenses
  • Fosun Cancer Hospital Guangzhou has built a robust international healthcare network,
  • with 8 core institutions dedicated to serving global patients.

Why Choose Us

  • 26,000+
    Over 26,000 international patient visits from 124 countries and regions.
  • 1,000+
    Over 1,000 cancer patients treated with our sixth-generation CyberKnife.
  • 800+
    Over 800 patients treated with the da Vinci Surgical System since April 2023.
  • 500+
    Personalized treatment plans developed for over 500 patients through China–U.S. MDT consultations.

Why Choose Us

  • 26,000+
    Over 26,000 international patient visits from 124 countries and regions.
  • 1,000+
    Over 1,000 cancer patients treated with our sixth-generation CyberKnife.
  • 800+
    Over 800 patients treated with the da Vinci Surgical System since April 2023.
  • 500+
    Personalized treatment plans developed for over 500 patients through China–U.S. MDT consultations.